Elevated Leukocyte Azurophilic Enzymes in Human Diabetic Ketoacidosis Plasma Degrade Cerebrovascular Endothelial Junctional Proteins.

Crit Care Med

1Children's Health Research Institute, London, ON, Canada.2Department of Physiology and Pharmacology, Western University, London, ON, Canada.3Centre for Critical Illness Research, Lawson Health Research Institute, London, ON, Canada.4Department of Translational Bioscience, National Research Council Canada, Ottawa, ON, Canada.5Department of Medicine, Western University, London, ON, Canada.6Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.7Department of Paediatrics, Western University, London, ON, Canada.8Department of Clinical Neurological Sciences, Western University, London, ON, Canada.

Published: September 2016

Objective: Diabetic ketoacidosis in children is associated with vasogenic cerebral edema, possibly due to the release of destructive polymorphonuclear neutrophil azurophilic enzymes. Our objectives were to measure plasma azurophilic enzyme levels in children with diabetic ketoacidosis, to correlate plasma azurophilic enzyme levels with diabetic ketoacidosis severity, and to determine whether azurophilic enzymes disrupt the blood-brain barrier in vitro.

Design: Prospective clinical and laboratory study.

Setting: The Children's Hospital, London Health Sciences Centre.

Subjects: Pediatric type 1 diabetes patients; acute diabetic ketoacidosis or age-/sex-matched insulin-controlled.

Measurements And Main Results: Acute diabetic ketoacidosis in children was associated with elevated polymorphonuclear neutrophils. Plasma azurophilic enzymes were elevated in diabetic ketoacidosis patients, including human leukocyte elastase (p < 0.001), proteinase-3 (p < 0.01), and myeloperoxidase (p < 0.001). A leukocyte origin of human leukocyte elastase and proteinase-3 in diabetic ketoacidosis was confirmed with buffy coat quantitative real-time polymerase chain reaction (p < 0.01). Of the three azurophilic enzymes elevated, only proteinase-3 levels correlated with diabetic ketoacidosis severity (p = 0.002). Recombinant proteinase-3 applied to human brain microvascular endothelial cells degraded both the tight junction protein occludin (p < 0.05) and the adherens junction protein VE-cadherin (p < 0.05). Permeability of human brain microvascular endothelial cell monolayers was increased by recombinant proteinase-3 application (p = 0.010).

Conclusions: Our results indicate that diabetic ketoacidosis is associated with systemic polymorphonuclear neutrophil activation and degranulation. Of all the polymorphonuclear neutrophil azurophilic enzymes examined, only proteinase-3 correlated with diabetic ketoacidosis severity and potently degraded the blood-brain barrier in vitro. Proteinase-3 might mediate vasogenic edema during diabetic ketoacidosis, and selective proteinase-3 antagonists may offer future vascular- and neuroprotection.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCM.0000000000001720DOI Listing

Publication Analysis

Top Keywords

diabetic ketoacidosis
48
azurophilic enzymes
24
diabetic
12
ketoacidosis
12
polymorphonuclear neutrophil
12
plasma azurophilic
12
ketoacidosis severity
12
azurophilic
8
ketoacidosis children
8
children associated
8

Similar Publications

The study was aimed at assessing the role of the MiniMed780G system of glycemic control before, during, and after Ramadan among people with Type 1 diabetes (PwT1D). This is a single-center retrospective analysis of MiniMed780G system users aged 14 years and above whose glycemic profiles were collected from February 21 to May 20, 2023, which corresponds to the Hijri months of Sha'ban, Ramadan, and Shawwal 1444/1445. Data was collected, processed, and analyzed in the framework of the Medtronic Galaxy service of the One Hospital Clinical Service (OHCS) program in Dallah Hospital, Riyadh, Saudi Arabia.

View Article and Find Full Text PDF

Aim And Background: Fluid resuscitation is the first-line treatment for patients with diabetic ketoacidosis (DKA). However, the optimal choice of resuscitative fluid remains controversial. This study aims to evaluate the impact of balanced electrolyte solution (BES) compared to 0.

View Article and Find Full Text PDF

Intravenous Fluid Prescription in Diabetic Ketoacidosis: Where is the Evidence?

Indian J Crit Care Med

January 2025

Department of Critical Care Medicine, Max Super Speciality Hospital, Lucknow, Uttar Pradesh, India.

Ghosh S. Intravenous Fluid Prescription in Diabetic Ketoacidosis: Where is the Evidence? Indian J Crit Care Med 2025;29(1):10-11.

View Article and Find Full Text PDF

A Case of Euglycemic Ketoacidosis Secondary to Continuous Renal Replacement Therapy.

Case Rep Crit Care

January 2025

Division of Pulmonary, Critical Care & Sleep Medicine, Keck Hospital of USC, Los Angeles, California, USA.

Euglycemic ketoacidosis (EKA) has been reported as a rare but life-threatening complication of continuous renal replacement therapy (CRRT). EKA should be suspected in the setting of persistent high anion gap metabolic acidosis despite renal replacement therapy. Critically ill patients, especially those with diabetes mellitus, are at risk of EKA due to deficient caloric intake, the presence of excess counterregulatory stress hormones, and nutritional losses from CRRT.

View Article and Find Full Text PDF

Quantifying the Deficits of Body Water and Monovalent Cations in Hyperglycemic Emergencies.

J Clin Med

December 2024

Research Service, Department of Medicine, Raymond G. Murphy Veterans Affairs Medical Center, University of New Mexico School of Medicine, Albuquerque, NM 87108, USA.

Hyperglycemic emergencies cause significant losses of body water, sodium, and potassium. This report presents a method for computing the actual losses of water and monovalent cations in these emergencies. We developed formulas for computing the losses of water and monovalent cations as a function of the presenting serum sodium and glucose levels, the sum of the concentrations of sodium plus potassium in the lost fluids, and body water at the time of hyperglycemia presentation as measured by bioimpedance or in the initial euglycemic state as estimated by anthropometric formulas.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!